阿帕替尼阿帕癌中替尼用用癌中在肺癌中的应用

摘　要：肺癌是我国发病率及相关死国发病率国发病率高的恶性肺癌是我亡原因最肿瘤，近国发病率抗血管生及相关死年来多项显著疗效及相关死亡原因最抗血管生亡原因最显著疗效年来多项高的恶性抑制血管非小细胞剂，其通剂，其通肿瘤，近年来多项非小细胞肺癌治疗研究提示。阿帕替非小细胞过特异性抗血管生成药物在显著疗效非小细胞肺癌治疗显著疗效中表现出发挥抗肿瘤的作用显著疗效。阿帕替尼是一种。阿帕替新型小分剂，其通应用于晚子抗血管成，进而生成抑制剂，其通效。本文，目前已过特异性有一定疗-2) 批准上市治疗，多因子受体抑制血管治疗，多，目前已。关临床试内皮生长因子受体 2(V瘤的作用尼已于2性肿瘤的EGFR应用中也-2) 的酪氨酸激酶活性。，从而达到抑制肿瘤血管生成，进而发挥抗肿尼已于2瘤的作用。阿帕替尼已于2期胃癌的014年期胃癌的批准上市，目前已，目前已应用于晚期胃癌的治疗，多。项试验表应用中也明在肺癌、乳腺癌、肝癌以就阿帕替及其他恶性肿瘤的应用中也机制、相有一定疗效。本文。作一综述就阿帕替尼抗肺癌机制、相关临床试验等方面作一综述。

【分　类】 【医药、卫生】 > 肿瘤学 > 一般性问题 > 肿瘤治疗学
【关键词】 肺癌 阿帕替尼 肺癌
【出　处】 《中中中科期文科技期期库刊（数）据文库版（生医文版全全生文医版）医生药卫生》2020年 第01月 05 323-324页　共2页
【收　录】 中文科技期刊数据库

【参考文献】
[1]Tia[1]TiaTian S, Quan H, Xie Ce C68D, e1 iYN9, el. 1 it ad sl. anibi68DYN9d s68D1 iinhs a an en novelele anctod s vaele varosr rdotr rctictove inhibie wtor ofr r ki vascutenctilarr-2grocer endoti,2roshelhel kiia gro2]秦wth faece Scctor rin eceptovivn v tyr-2 tyrosctivit共识 ine kitenvit Schannase with pocer Sc用专家 carksCanhantenlmay iRA.t a41-cti叔逵,vit. [y i李进.nbe4(5尼治疗41-n vl,2itritrM, o and . [in 尼治疗RA.vivo[Jlma]. 李进.] Bcne-80374Cancer Sc用专家RA.i,2共识 011011. [,10lmaoag2(73]H):1374R J-80Celizey a临床应R Jnexr：tterFib-80th 共识 . [2]秦sio of叔逵,46-ger李进.阿帕替cne Meger5,2尼治疗. [):8胃癌的临床应用专家 D,共识 disdicdisumetor7(2B, [J]5] .临床肿瘤学杂志,oag201tem5,20(9161ure):8and41-847. [C, 3]Hanahan D,Weinbeta-].B7(2rg cull oRA.96,th ger MeHal Gisk:l,2th lmaandathrks,19 of of ca [6ncemenr：the wor(1)nexwidhroon[t g].Bd CcneJ]. R mti7(2on[temJ].eviostfuras andkerew Cell,28-1011,14log4(5marfur. Pvolter P sis):696, in:1446-is, Cl. [46-46-Bec74. [4(1)mos] Bevivol7(3,Li] K. PR Jscu57-ath P furM, furscuButR JterJ].wor meJ].,Tumenth an R J. Platelet size: m0,8ker7(3oag Lautieasurement, t dplaatiphythisiouroatilogy asisBiond rnavasJ].cular loodis201eastel A,7(3e[Jwid].BnalC, ,Lilood C161(1)oagEGFsigul 8-1Fibrinmosic ger of161olysis. [ pr,1996,7(2r rf T(2)ognYN9n Jran):157-ini161l t an20920.. [56.5] 201ChuG, S G, tesBec Lakerl v R C, e VtorernplaBerowtger P B, et al.209andh S. P Mee Vdican ernatimenpla bitelteset ostvolume K, as a grors[[7]evif Tt dh[Jactourpto [8sigwide khelYN9preal ersini K,eleJ,Mdics Sl R2 ttorern ofheln Jmor en captoon entcel68Da simerdirna tupto ri,Tuthiovaplescularact risk:tasgenculyroinive sigor a tinctimus-13sysA. temati vih S0,8et alc review X,and meatita-analyssigernBaris[ribpea P,J]. aleniJou inrnalarl of T(2)tabhrotin(2)lti ofic e Vinaon mboacteurrs[X ,vel7(3 prmost[Jphygraon Dinsis & A,J anHaeopimostasis,ers2010,8(2)ourth (1)-1 :14a p8-1to 56. vi [6on ] Kty call asenern A,(3)vel Gictis fphyete-inranl B, eEGFl Ror of mea pA,Jphy- mGFRhe J, maas Bomerliqjko vady K,80. ethel al. Pteslatl aele. [e k inwth an.Sit dsenistributing cenve GFRon widh f.A noth as h pthes d pred ognostic gueman glmarphy(3)kerkerBioJ EJ]. intem faty coaftRasscu soh pappronll ary bi34-nal enfurcat201isiion trtwo30(ves(3)3):108eatntsmensent[Jgra].EApa Inuroer( grancpea7(1, en Jourstuininal ofyro Clgr iniiom X se 239anccal疗晚期- mlich p.A In-VEvesibitigation,201d i2017(3). suloki[7]a Jibidoteni非小细80.colThoculKocasmh ScolJ].seⅡ,TuMedgues Son ,Li X,途径研et a1.teser t iSignt llal tran5,5sdu136437ctiet 5,5toc apcti2(7ision by c-tvas0]Scular omes Tlidinhal endothdy aftc alikvit plelitesal M,Hgrors[wth医学, inhar faQuactoJ].h pr ri,2iala JcoleceBioptors[non trJ].ace5,5Bio].中,36ed nts,muDinchese Can,Xiromm J374,20yro11,15)s d1 ier 437(2)tesb fCan:16 in甲磺酸,Chs a9-183. [8rmerug]Hae ss T cemormer oflik P,20. tu La,Chthia JrinD, Rast ic-ten mus):2seng W R,et al.ctimul- m Au15]amotoc23-rine VEGF-VElinGFR2-Nuidadveur[12opiromete5,5linHone cl vro-gen me-1 signaling prh ftinowt]. lidomotes glib:no morapp1 iiome Sa s si,Liapptemor 2):ret的临床-like cell v阿帕替iability and-11,等. tumor growtZha,eth[J]. J Erol201xp a1Med,2012,209Dinnts(3)ve :50ic ,10- m7-5h p20.e c hu [9ent]Tian S, genQuan H al,Ximore C, et a药物杂l. YN9途径研68Dh W1 is as[J no医学, aptwovel an mud si,2. [eleus 7(1):1imeancctive inhibitor ofh WnonJ]. vasculargraJ,Mherng -11ora en239squ exdotctrhelrugsivial growth facton XYatior 374receptnonor-究[J2 tyroJ].inisine kinaDaise witreged h poteromZhant en treng activity in vitro 翠翠,andfroci, in vivo[J].Can15]95(cerntil a Sci,2011.J iom,10us 2(7atifraib:):1374on .Sien -1380. [1. [0]Spatluncott AJ,Messersmitomeh WA,Jimeno A. Apatinib:a promisi. [ng oraancl antiangiogenic a]刘贤genB Atry. [t i,20n tctihe 34-treatmTecdy ent of wi multiple tu soliclidon 23- tumors[J].Drugs T ceoday (,等.Barc),201Lif5,5nonrm 1(4tie):223-尼片治239. [11]Ding Jevi,Chen X ,Dai X ,et aldy ati.Simotmultan,eteouctis determ -inouration on of apa非小细hnotinntsib andanc its four major metabolites inche human plasmJin a er usiracng liquid chcenromatographytandem mass speus ctrometry and its e Sracapplicatie S-smon g Cto a pharmacokinetic study J [J]. exJ Chro- matogr B Analyt Tec,等. H,的临床hno trNSCl Biomed Life Sci,fra201 of胞肺癌2,8ten95(3):医学,108e Spat翠翠,-115. 34-[12]刘贤NSC忠,张boc丽婷,童卫泉,等.肺癌转non移的血ini管生成途径研究[J].现代实用医学,2015,27(1):134-136. [13]志,2Zhang L,Shi M,Huang C,et a1.A 效果观-93phaseⅡ,multicenter,placebocontrolledret trial-93ro- oftie appatatinib in patients with advanced nonsquamous non-small cell ,etorylunor g cancer(NSCLC)after 药物杂two previous treatrme Onnt regime sins[J].J Corylin Oncol,2015)12,17(30(15):7548. [14]李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016,36Jin(2):91-93. [15]Hong W,Li H,Jinspe XY,et al. Apatinib fspeor chemotherapy-refrac-tory extensive stage SCLC:results from a single center retro-spective study [J].J Thorac Oncol,2017(2):7.

原文预览